Zhenchuan Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied under the manufacturing model designation ZC-VAPI-VG as a dry standardized powder for multi-route formulation. The product is distinguished from unprocessed herbal material by standardized active marker content and particle size engineering; the powder is not a simple milled herb but a dry extract prepared for multi-route formulation. The dry matrix is released against a compendial and physical test panel that includes identity, assay, residual solvents, elemental impurities, loss on drying, residue on ignition, bulk and tapped density, particle size distribution, and microbial enumeration. For parenteral use, bacterial endotoxin testing is added under USP <85>, and the release limit is derived from the intended dose, species, and route rather than a default fixed value. The powder is packed in sealed HDPE drums with double food-grade polyethylene liners and is stored at 15–25 °C with ambient relative humidity controlled to ≤ 35 % RH. Re-sealing under dry nitrogen is applied when the powder is intended for moisture-sensitive tablet or capsule work. The API is not released as a sterile final product; terminal sterilization or aseptic filtration of the finished injection is required after dissolution.

Release Is Governed by Compendial Methods and Physical Tests

The release panel is defined by validated methods under USP <621> for chromatographic identity and assay, USP <731> for loss on drying, USP <281> for residue on ignition, USP <616> for bulk and tapped density, USP <429> for particle size distribution by laser diffraction, USP <61>/<62> for microbial enumeration, and USP <85> for bacterial endotoxins when the intended route is parenteral. Assay is expressed on the dried basis, and the active marker compound is measured against a qualified reference standard. Residual solvent evaluation follows ICH Q3C; Class 2 and Class 3 solvents are quantified by headspace gas chromatography, and the API is released only when residual levels fall below the concentration limits in the guideline. Elemental impurities are assessed according to ICH Q3D; the permitted daily exposure is applied to the final veterinary dosage form rather than to the API alone, and the contribution of the API is described in the finished-product risk assessment. Particle size is routinely reported as D10, D50, and D90; the D90 upper limit is set at 150 µm to support capsule and tablet blending, while the D10 lower limit is controlled at or above 20 µm to reduce dusting. Bulk and tapped density values are used to calculate the compressibility index and Hausner ratio under the principles of USP <1174>. Because no harmonized monograph exists for this specific multi-route veterinary grade, batch-specific acceptance criteria in the manufacturer’s certificate of analysis govern release.

Powder Flow and Dose Uniformity Constraints in Dry Blending

For tablet and capsule manufacture, the dry API is incorporated by direct compression or wet granulation. Direct compression is not used when the compressibility index, calculated from bulk and tapped densities under USP <616>, is above 25 %. On a 200 L V-blender fitted with an intensifier bar, a geometric dilution sequence is required when the active fraction is below 2.0 % w/w; blending at 12 rpm for 15 min is used before final lubrication. Hopper ratholing is observed above 55 % ambient RH on a rotary tablet press when the powder moisture exceeds the loss-on-drying limit. Therefore, pre-drying in a fluid-bed dryer at 40 °C for 2 h is applied if loss on drying exceeds 1.0 % before dry blending. On a high-speed rotary press with turret speed above 70 rpm, moisture above 1.0 % has been associated with capping and lamination when the formulation contains microcrystalline cellulose and croscarmellose sodium; this is a processing boundary rather than an API failure. Capsule fill weight is monitored on an automatic checkweigher every 30 min, with the filled mass controlled to ± 3.0 % of target. Blend uniformity and content uniformity are assessed by USP <905>; for low-dose formulations, the acceptance value applies to the finished tablet or capsule, not to the API alone.

Wet granulation endpoint is controlled by impeller torque and power consumption rather than time alone. In a 65 L high-shear granulator, the powder mass is dry-mixed for 2 min at 100 rpm; binder solution is then sprayed at 0.15 kg/min until the torque curve inflects upward. Endpoint is defined as a 20–25 % increase in steady-state torque from the dry-mix baseline, not by a fixed granulation time. Over-granulation appears as a rapid torque rise and produces dense granules that resist compression; under-granulation leaves fines that segregate during transfer. The wet mass is discharged through a 10-mesh screen and dried in a fluid-bed dryer to a final moisture of 3.0–5.0 %. Granule size distribution is then measured by sieve analysis; the target fraction on 20-mesh is not more than 10 %, and the fraction below 80-mesh is not more than 25 %. This distribution stabilizes compression and supports content uniformity under USP <905>.

When the API Is Specified for Premix and Granule Lines

For feed premix and granule applications, the powder is diluted with calcium carbonate or dextrose monohydrate to a final active concentration in the range of 0.5–2.0 % w/w. A 500 kg ribbon blender with 10 rpm agitator speed is used; the API is added last to reduce static adhesion to the vessel walls. Free-fall transfer segregation is observed when the carrier particle size D90 exceeds 250 µm; the API is therefore milled to a D90 of 150 µm or below. Percolation segregation occurs when the active D90 is below 50 µm and the carrier is coarser than 300 µm; the narrow D10-to-D90 band of this grade reduces that risk. The blend is discharged into FIBCs with liner antistatic film; dusting is controlled by maintaining fill flow below 5 kg/min. Where a granule form is required, the blend is further processed by dry roller compaction or wet granulation; the resulting granules are screened through an 18-mesh screen. Final premix moisture is confirmed by USP <731>, and the active content is tested by compendial assay with acceptance criteria defined in the registration dossier.

How Does the Multi-Route Grade Differ from Single-Route Veterinary Powders?

The principal difference is not pharmacological identity but the release test envelope and physical control strategy. A conventional feed-grade powder may be released only for assay, loss on drying, and sieve fraction, with particle size expressed as percent passing 0.45 mm and 0.15 mm sieves. In this product, the same API is additionally controlled by laser diffraction under USP <429>, bulk and tapped density under USP <616>, endotoxin under USP <85>, bioburden under USP <61>/<62>, elemental impurities under ICH Q3D, and residual solvents under ICH Q3C. This creates an input stream suitable for sterile filtration and high-shear tableting; a single-route premix powder would not meet the microbial or particle size requirements for parenteral use. The particle size window is narrower than conventional botanical powders: the D10 is maintained at or above 20 µm to reduce dusting, and the D90 is maintained at or below 150 µm to improve blend homogeneity. Unmicronized botanical powders often exhibit D90 values above 250 µm and require pre-milling before tableting. The product is supplied with documentation that includes ICH Q3D and ICH Q3C compliance data, which is not standard in all single-route feed powders. No direct multi-lot head-to-head clinical comparison is publicly available; the differences are derived from release test requirements and physical process limits.

Solubility, pH, and Rheological Considerations in Liquid Compounding

In solution compounding, the dry powder is added to a vortex in a stainless steel jacketed vessel at 20–25 °C. Moderate agitation at 300–500 rpm is maintained for 20 min; high-shear mixing above 2,000 rpm is avoided because it entrains air and generates foam that is not removed by 0.22 µm filtration. pH is measured after complete dissolution; if the range falls outside 5.5–7.5, citrate or phosphate buffer is added in 0.1 M increments until the target is reached. The solution is then filtered through 0.45 µm and 0.22 µm membranes and transferred to filling under nitrogen if oxidative degradation is a concern. Viscosity of the final solution is expected to remain below 10 mPa·s at 25 °C for typical concentrations; published data for this specific configuration are limited and the viscosity should be confirmed on the formulation batch. Strongly alkaline buffers above pH 8.5 should be avoided because precipitation and loss of active marker may occur. For oral solutions, the same pH and filtration controls are used, but sterility is replaced by microbial limits under USP <1111>.

If Terminal Sterilization Is Replaced by Aseptic Filtration

Parenteral preparation from the dry API follows a closed processing sequence. The powder is dissolved in Water for Injection at 20–25 °C; the solution is pre-filtered through a 0.45 µm membrane and then sterilized through a 0.22 µm sterilizing-grade filter. The pre-filtration bioburden is monitored and maintained below 10 CFU/100 mL; this is a process control limit, not a compendial release test, and it is derived from filter validation risk assessment under the principles of USP <1227> and parenteral manufacturing guidance. Filter integrity is tested before and after processing by bubble point or pressure hold testing; the filter manufacturer’s water-based bubble point for 0.22 µm PVDF filters is typically reported in the range of 2.5–3.5 bar but the acceptance value must be filter-lot-specific. The final sterility test is performed by USP <71>. Endotoxin limits are calculated from the formula in USP <85> using maximum dose, species body weight, and route-specific K values; no fixed endotoxin acceptance criterion is assigned to the dry powder without the intended dose.

Compliance documentation for the multi-route powder includes a certificate of analysis, residual solvent data under ICH Q3C, elemental impurity data under ICH Q3D, and nitrosamine risk assessment records under ICH M7. For sterile injections, the manufacturing file must include filter validation data for the 0.22 µm membrane, container–closure integrity testing, and bacterial endotoxin testing by USP <85>. The powder’s operational boundaries are: avoid open handling above 60 % RH, avoid strongly alkaline pH above 8.5, and avoid high-shear mixing above 2,000 rpm during solution preparation. If the product is transferred to another manufacturing site, revalidation of blend uniformity and particle size distribution is required because particle attrition during pneumatic conveying can shift D90 and affect content uniformity.